# Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00072072** · PHASE1 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** celecoxib
- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00072072
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** — (—)
- **Last updated:** 2013-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072072, "Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00072072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*